Multilayer composite material

Patent metadata

Field	Value
Publication number	US-12447134-B2
Application number	US-202318196710-A
Country	US
Kind code	B2
Filing date	May 12, 2023
Priority date	Feb 26, 2018
Publication date	Oct 21, 2025
Grant date	Oct 21, 2025

Abstract

The present invention relates to a multilayer composite material for the treatment of wounds and lesions and to a dressing comprising said multilayer material.

First claim

The invention claimed is:

1. A multilayer composite material (CM) comprising at least:
a) a three-dimensional matrix comprising at least a first layer and a second layer of a fabric comprising a polyester fiber, wherein said first layer and said second layer are superimposed and welded together in at least two distinct and separate points, to form a cage which contains a healing substance which is released homogenously, uniformly and constantly over time, and so as to define a space S between the first layer and the second layer; and
b) a composition comprising
at least one natural, semi-synthetic or synthetic polymer, possibly mixed together;
possibly one or more pharmacologically and/or biologically active substance, and
at least one excipient suitable for pharmaceutical use,
wherein said composition b) is contained in at least a part of said space S included between the first layer and the second layer,
said composition being distributed uniformly throughout the space S defined by the first layer and the second layer of the matrix a) and, at least in part, on the surfaces of the first layer and the second layer that are external to the space S;
said composition b) contained in the three-dimensional matrix a) being in different pharmaceutical forms selected among creams, ointments, emulsions, gels, hydrogels, water-based solutions, non-water-based solutions, or suspensions.

2. The multilayer composite material (CM) according to claim 1 , wherein the natural or semi-synthetic polymers are polysaccharides, proteins, polypeptides or polynucleotides; the synthetic polymers are polyacrylic acid; polyaspartamide; poly(ethyleneglycol) (PEG); polyvinyl-pyrrolidone; polyanhydrides; polyorthoesters; polyphosphoesters; polyphosphazenes; polycyanoacrylic derivatives; poly(N-isopropylacrylamide); polylysine; polyhistidine; polyamidoamine; or polyglutamic acid.

3. The multilayer composite material (CM) according to claim 2 , wherein the polysaccharides are selected from:
glycosaminoglycans;
chitin, chitosan and its derivatives;
pectin or pectinic acid;
galactans;
glucans;
xanthan, gellan;
fructans;
polymannans; and
carrageenan.

4. The multilayer composite material (CM) according to claim 2 , wherein the proteins or polypeptides are:
collagen, co-precipitates of collagen and glycosaminoglycans, gelatin, elastin, keratin, silk, silk fibroin alone or in combination with sericin, or silk sericin.

5. The multilayer composite material (CM) according to claim 1 , wherein the pharmacologically and/or biologically active substances are natural extracts of a natural or synthetic origin; drugs for topical use; steroids; antibacterials/antibiotics; cytostatics; growth factors; fibrinolytic and antiedematous substances; proteolytic enzymes; hyaluronidase; or anticoagulants.

6. The multilayer composite material (CM) according to claim 1 , wherein the composition b) comprises:
sodium salt of hyaluronic acid (HA), prepared starting from hyaluronic acid having a weight average molecular weight ranging from 150 to 2,000 kDa optionally in association with another polysaccharide,
optionally a protein selected from silk fibroin and collagen, and
optionally pharmacologically and/or biologically active substances.

7. The multilayer composite material (CM) according to claim 1 , wherein the composition b) comprises:
sodium salt of hyaluronic acid (HA), prepared from hyaluronic acid having a weight average molecular weight ranging from 150 to 250 kDa, or hybrid complexes of high- or low-molecular-weight hyaluronic acid or a mixture thereof,
optionally a protein selected from silk fibroin and collagen, and
optionally associated with pharmacologically and/or biologically active substances.

8. The multilayer composite material (CM) according to claim 1 , wherein the composition b) further comprises metallic silver or at least one silver salt or complex.

9. The multilayer composite material (CM) according to claim 1 , wherein the fabric of the first layer and/or of the second layer is a monofilament fabric.

10. The multilayer composite material (CM) according to claim 1 , wherein the fabric of the first layer and/or of the second layer comprises at least one of polyethylene terephthalate (PET), or a natural polyester.

11. The multilayer composite material (CM) according to claim 1 , wherein the fabric of the first layer and/or of the second layer contains from 10 to 15 meshes, vertically, and from 10 to 17 meshes horizontally.

12. The multilayer composite material (CM) according to claim 1 , wherein the fabric of the first layer and/or of the second layer are welded by means of points obtained by welding so as to obtain points at a distance ranging from 10 to 20 mm from one another.

13. The multilayer composite material (CM) according to claim 1 , or a dressing comprising said multilayer composite material (CM) for the use in the treatment of a wound, abrasion, cut, ulcer, sore, burn, lesion or laceration of the skin in a subject, wherein said treatment comprises the application of said multilayer composite material on the surface of the wound, abrasion, cut, ulcer, sore, burn, lesion or laceration of the skin and, optionally, of the underlying tissues.

14. The multilayer composite material (CM) according to claim 2 , wherein the synthetic polymers are pHEMA [poly-2-hydroxyethyl-methacrylate]; polylactic-co-glycolic acid (PLGA), polyglycolic acid (PGA), or polycaprolactone.

15. The multilayer composite material (CM) according to claim 1 , wherein the synthetic polymers are polyurethanes.

16. The multilayer composite material (CM) according to claim 3 , wherein the
glycosaminoglycans are selected from hyaluronic acid and/or derivatives thereof selected from salts, esters, amides and sulfated hyaluronic acid; hybrid complexes of high- and low-molecular-weight hyaluronic acid; chondroitin, chondroitin sulfate, dermatan sulfate, keratansulfate, heparan sulfate, heparin and heparinoids;
chitosan is chitosan derivatized with lactose;
galactans are agar or agarose;
alginates are alginic acid;
glucans are selected from dextran, dextrin, trehalose, maltose, starch, cellulose and its derivatives; and
fructans are inulin.

17. The multilayer composite material (CM) according to claim 5 , wherein the drugs for topical use are non-steroidal anti-inflammatory drugs (NSAIDs); antibacterials/antibiotics are silver sulfadiazine; cytostatics are metallic silver; and proteolytic enzymes are collagenases.

18. The multilayer composite material (CM) according to claim 6 , wherein the sodium salt of hyaluronic acid (HA) is prepared starting from hyaluronic acid having a weight average molecular weight ranging from 150 to 500 kDa.

19. The multilayer composite material (CM) according to claim 6 , wherein the sodium salt of hyaluronic acid (HA) is prepared starting from hyaluronic acid having a weight average molecular weight ranging from 150 to 250 kD.

20. The multilayer composite material (CM) according to claim 6 , wherein the optionally pharmacologically and/or biologically active substances is in combination with silver sulfadiazine.

21. The multilayer composite material (CM) according to claim 8 , wherein the composition b) comprises silver sulfadiazine.

Assignees

• Fidia Farm Spa

Inventors

• Gennari Giovanni
• Campisi Monica
• Zanellato Anna Maria

Classifications

• A61K47/36

  Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin · CPC title

• A61K47/34

  Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61K38/39

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] · CPC title

• A61K33/38

  Silver; Compounds thereof · CPC title